New brain cancer drug targets tumor growth signals
NCT ID NCT06072586
Summary
This early-stage study is testing an experimental drug called BDTX-1535 in people with aggressive brain tumors (high-grade glioma or glioblastoma) that have specific genetic changes in a protein called EGFR. The research aims to see if the drug reaches brain tumor tissue effectively and can be given safely. Participants will take the drug before planned tumor removal surgery, allowing researchers to measure drug levels in the tumor and surrounding fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chandler Regional Medical Center
RECRUITINGChandler, Arizona, 85224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Joseph's Hospital and Medical Center
RECRUITINGPhoenix, Arizona, 85013, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.